Alpha-1 Antitrypsin Deficiency: Bridging Care
The landscape of alpha-1 antitrypsin deficiency-associated liver disease is evolving, with advances in therapeutic strategies and management. Featuring expert insights from multiple specialists, this resource aims to provide you with the information you need to ensure early diagnosis of alpha-1 antitrypsin deficiency and deliver the best care for your patients.
Check back here over the next 12 months to:
- Watch an accredited symposium on alpha-1 antitrypsin deficiency – chaired by Rohit Loomba at EASL 2025 – for the latest guidance on recognizing early signs of liver disease and ensuring liver health in asymptomatic patients
- Listen to specialists discussing the burden of alpha-1 antitrypsin deficiency-associated liver disease and the underlying genetic risk factors, in our accredited podcast series
- Watch exclusive interviews to hear first-hand perspectives from primary care physicians, hepatologists, pulmonologists, gastroenterologists, geneticists, patient advocates, and clinical researchers
EASL 2025 symposium
Watch Rohit Loomba and colleagues discuss identifying and managing alpha-1 antitrypsin deficiency-associated liver disease
of interest
are looking at
saved
next event
Developed by EPG Health. This content has been developed independently of the sponsor, Takeda, which has had no editorial input into the content. EPG Health received funding from the sponsor to help provide healthcare professional members with access to the highest quality medical and scientific information, education and associated relevant content. This content is intended for healthcare professionals only.